Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Becton Dickinson and Co | 242 |
| 2 | F Hoffmann La Roche AG | 214 |
| 3 | 10X Genomics Inc | 174 |
| 4 | University of California San Diego UCSD | 143 |
| 5 | Harvard University | 130 |
| 6 | Leland Stanford Junior University | 116 |
| 7 | Regeneron Pharmaceuticals Inc | 114 |
| 8 | Institut National de la Sante et de la Recherche Medicale INSERM | 102 |
| 9 | Amgen Inc | 100 |
| 10 | Massachusetts Institute of Technology | 96 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 7,055 |
| 2 | A61P | Therapeutic activity (drug indications) | 6,072 |
| 3 | C07K | Peptides | 5,044 |
| 4 | C12N | Microorganisms, enzymes | 3,998 |
| 5 | G01N | Investigating / analysing materials | 3,546 |
| 6 | C12Q | Measuring/testing involving enzymes | 3,015 |
| 7 | Y02A | Climate change adaptation | 1,064 |
| 8 | C07D | Heterocyclic compounds | 613 |
| 9 | C12Y | Enzyme nomenclature (EC numbers) | 430 |
| 10 | B01L | 303 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Nanoplatforms for cancer theranostics | 2 |
| 2 | Optical Imaging and Spectroscopy Techniques | 2 |
| 3 | S100 Proteins and Annexins | 2 |
| 4 | Cancer Research and Treatments | 1 |
| 5 | Cardiac Imaging and Diagnostics | 1 |
| 6 | Lanthanide and Transition Metal Complexes | 1 |
| 7 | Lymphatic System and Diseases | 1 |
| 8 | Monoclonal and Polyclonal Antibodies Research | 1 |
| 9 | Nanoparticle-Based Drug Delivery | 1 |
| 10 | Nitric Oxide and Endothelin Effects | 1 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Andreas Faust | University of Münster | 9 |
| 2 | Christoph Bremer | University Hospital Münster | 9 |
| 3 | Alexei Bogdanov | Massachusetts General Hospital | 8 |
| 4 | Ick Chan Kwon | Korea Institute of Science and Technology | 8 |
| 5 | Anna Moore | Massachusetts General Hospital | 7 |
| 6 | Carsten Höltke | University Hospital Münster | 7 |
| 7 | Ralph Weissleder | Massachusetts General Hospital | 7 |
| 8 | Catherine Cannet | Novartis Institutes for BioMedical Research | 3 |
| 9 | Kwangmeyung Kim | Korea Institute of Science and Technology | 6 |
| 10 | Lee Josephson | Harvard University | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. | 2003 | 549 | Nanoplatforms for cancer theranostics |
| Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci | 2007 | 417 | Angiogenesis and VEGF in Cancer |
| Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring | 2010 | 349 | Nanoparticle-Based Drug Delivery |
| Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V–Cy5.5 conjugate | 2004 | 347 | Nanoplatforms for cancer theranostics |
| In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts | 2004 | 346 | Immunotherapy and Immune Responses |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of this compound?
What are the primary research topics associated with patents and papers involving this compound?
Which organizations hold the most patents related to this compound?
What patent classification codes are most prominent for this compound?
Who are the leading researchers publishing on topics related to this compound?